BC Extra | Oct 4, 2019
Company News

Icosavax’s self-assembling vaccine platform

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its...
BC Extra | Sep 19, 2019
Preclinical News

Sept. 19 Preclinical Quick Takes: Celsius' single-cell analysis; plus Merck's RSV therapy, glial cell transplant and methylation profiles for tumors

Celsius gets three single-cell analysis partners  Through separate deals, Celsius Therapeutics Inc. partnered with the Parker Institute for Cancer Immunotherapy, Institut Gustave-Roussy and University Health Network to apply its single-cell genomics platform, which includes machine-learning...
BC Extra | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

AB Sciences drops masitinib for melanoma  AB Science S.A. (Euronext:AB) halted development of masitinib for metastatic melanoma despite reporting that the product led to a 33.3% overall response rate (ORR), the primary endpoint in the...
BC Innovations | Jun 7, 2019
Distillery Therapeutics

CRISPR-edited B cells treat RSV

DISEASE CATEGORY: Infectious disease INDICATION: Respiratory syncytial virus (RSV) Mouse studies suggest CRISPR-edited B cells that secrete engineered anti-RSV F protein antibodies could help treat RSV infection. Generation of the cells involves editing primary B...
BC Innovations | Mar 19, 2019
Distillery Therapeutics

RSV F protein-based nanoparticle vaccine for RSV infection

DISEASE CATEGORY: Infectious disease INDICATION: Respiratory syncytial virus (RSV) Mouse and non-human primate studies suggest an RSV F protein-based nanoparticle vaccine could help prevent RSV infection. The self-assembling nanoparticles consist of a core of 12...
BC Week In Review | Mar 1, 2019
Clinical News

Novavax's RSV vaccine misses in Phase III in infants

Novavax Inc. (NASDAQ:NVAX) said its ResVax RSV vaccine missed the primary endpoint in the Phase III Prepare trial to prevent respiratory syncytial virus infection in infants via maternal immunization. In the trial's per protocol population...
BC Week In Review | Nov 16, 2018
Clinical News

Ark's ziresovir stops worsening of RSV symptoms in Phase II

Ark Biosciences Inc. (Shanghai, China) reported data from the Phase II VICTOR trial in hospitalized infants with respiratory syncytial virus (RSV) infection showing that no infant who received a single dose of oral ziresovir (AK0529)...
BC Innovations | Nov 6, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Cell culture, mouse and rat studies identified an RSV F protein inhibitor that could help treat RSV infection. Optimization and testing in HeLa cell-based assays of a previously reported quinoline-based...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Cell culture and mouse studies identified an mRNA encoding a camelid-derived anti-RSV F protein antibody heavy chain that could help prevent RSV infection. The mRNA was modified to encode a...
BC Week In Review | Aug 3, 2018
Financial News

ReViral raises $55M series B

ReViral Ltd. (Stevenage, U.K.) raised $55 million in a series B round co-led by new investors New Leaf Venture Partners and Novo Ventures. Also participating in the round was fellow new investor Perceptive Advisors and...
Items per page:
1 - 10 of 91